The clinical utility of [18F]FNA-conjugates has been demonstrated by the success of Piflufolastat F-18 used in PET imaging of prostate-specific membrane antigen (PSMA)–positive prostate cancer lesions and metastases (Keam 2021). This evidence concerns the gene FOLH1 and prostate carcinoma.